SOPH
SOPHiA GENETICS S.A.
$5.68
-0.04
(-0.70%)
Mkt Cap
390.43M
Volume
120,863
52W Range
2.92-6.3
Sector
Healthcare
Beta
0.96
EPS (TTM)
-1.18
P/E Ratio
-3.99
Revenue (TTM)
81.18M
Rev Growth (5Y)
+22.2%
EPS Growth (5Y)
N/A
Company Description
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Net Income | (79.00M) | (62.49M) | (78.98M) | (87.45M) | (73.67M) | (39.34M) | (33.79M) |
| EPS | -1.17 | -0.95 | -1.22 | -1.36 | -1.33 | -0.82 | -0.53 |
| Free Cash Flow | (38.59M) | (51.00M) | (57.80M) | (80.47M) | (64.61M) | (34.93M) | (34.71M) |
| FCF / Share | -0.57 | -0.78 | -0.89 | -1.26 | -1.17 | -0.73 | -0.54 |
| Operating CF | (38.01M) | (42.82M) | (48.58M) | (70.09M) | (57.94M) | (31.73M) | (31.68M) |
| Total Assets | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M | 132.12M | 51.66M |
| Total Debt | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M | 7.25M | 8.46M |
| Cash & Equiv | 70.29M | 80.23M | 123.25M | 161.31M | 192.96M | 74.62M | 18.07M |
| Book Value | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M | 100.51M | 22.25M |
| Return on Equity | -1.68 | -0.65 | -0.52 | -0.44 | -0.27 | -0.39 | -1.52 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.69M | 21.71M | 19.46M | 18.32M | 17.78M | 17.73M | 15.85M | 15.81M | 15.78M | 17.05M | 16.30M | 15.05M |
| Net Income | (19.32M) | (19.18M) | (20.02M) | (22.41M) | (17.39M) | (15.16M) | (18.44M) | (15.19M) | (13.70M) | (24.06M) | (13.82M) | (21.40M) |
| EPS | -0.27 | -0.28 | -0.30 | -0.33 | -0.26 | -0.23 | -0.28 | -0.23 | -0.21 | -0.37 | -0.21 | -0.33 |
| Free Cash Flow | (17.06M) | (9.28M) | (8.90M) | (10.19M) | (12.24M) | (12.54M) | (9.48M) | (12.37M) | (16.60M) | (13.54M) | (14.27M) | (13.47M) |
| FCF / Share | -0.24 | -0.14 | -0.13 | -0.15 | -0.18 | -0.19 | -0.14 | -0.19 | -0.25 | -0.21 | -0.22 | -0.21 |
| Operating CF | (16.18M) | (8.94M) | (8.79M) | (8.21M) | (10.75M) | (10.60M) | (7.16M) | (10.42M) | (14.64M) | (11.29M) | (12.17M) | (10.32M) |
| Total Assets | 157.00M | 163.03M | 163.46M | 177.62M | 146.72M | 155.31M | 177.61M | 181.10M | 180.26M | 206.16M | 205.85M | 223.20M |
| Total Debt | 62.42M | 63.02M | 63.37M | 63.81M | 30.13M | 30.03M | 31.67M | 30.07M | 17.44M | 18.60M | 17.87M | 19.82M |
| Cash & Equiv | 65.39M | 70.29M | 81.61M | 94.82M | 68.53M | 80.23M | 95.79M | 105.40M | 103.73M | 123.25M | 132.77M | 148.55M |
| Book Value | 45.69M | 47.15M | 60.69M | 76.69M | 85.61M | 96.49M | 113.51M | 121.44M | 132.23M | 151.44M | 158.44M | 171.70M |
| Return on Equity | -0.42 | -0.41 | -0.33 | -0.29 | -0.20 | -0.16 | -0.16 | -0.13 | -0.10 | -0.16 | -0.09 | -0.12 |
SOPH News
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.